Cardiovascular Outcomes and Readmissions of Atrial Fibrillation Among Patent Foramen Ovale Occluder Device Recipients: A Propensity Matched National Readmission Study

Hagen, 1984, Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts, Mayo Clin Proc, 59, 17, 10.1016/S0025-6196(12)60336-X Meissner, 1999, Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Stroke prevention: assessment of Risk in a Community, Mayo Clin Proc, 74, 862, 10.4065/74.9.862 Lamy, 2002, Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Atrial septal aneurysm, Stroke, 33, 706, 10.1161/hs0302.104543 Homma, 2002, Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study, Circulation, 105, 2625, 10.1161/01.CIR.0000017498.88393.44 Chen, 2021, Atrial fibrillation following patent foramen ovale closure: systematic review and meta-analysis of observational studies and clinical trials, Stroke, 52, 1653, 10.1161/STROKEAHA.120.030293 Kent, 2016, Device closure of patent foramen ovale after stroke: pooled analysis of completed randomized trials, J Am Coll Cardiol, 67, 907, 10.1016/j.jacc.2015.12.023 Saver, 2017, Long-term outcomes of patent foramen ovale closure or medical therapy after stroke, N Engl J Med, 377, 1022, 10.1056/NEJMoa1610057 Lee, 2018, Cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE-PFO trial, J Am Coll Cardiol, 71, 2335, 10.1016/j.jacc.2018.02.046 Kleindorfer, 2021, 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association, Stroke, 52, e364, 10.1161/STR.0000000000000375 Søndergaard, 2017, Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke, N Engl J Med, 377, 1033, 10.1056/NEJMoa1707404 Staubach, 2009, New onset atrial fibrillation after patent foramen ovale closure, Catheter Cardiovasc Interv, 74, 889, 10.1002/ccd.22172 Oliva, 2021, New-onset atrial fibrillation following percutaneous closure of patent foramen ovale: a systematic review and meta-analysis, J Interv Card Electrophysiol, 60, 165, 10.1007/s10840-020-00925-5 Odutayo, 2016, Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis, BMJ, 354, i4482, 10.1136/bmj.i4482 Tanaka, 2021, Trends in cardiovascular mortality related to atrial fibrillation in the United States, 2011 to 2018, J Am Heart Assoc, 10, 10.1161/JAHA.120.020163 Healthcare cost and utilization in project (HCUP). Rockville, MD: Agency for Healthcare Research and Quality. https://www.ahrq.gov/data/hcup/index.html. StataCorp. 2021. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC. created with biorender.com. Khairy, 2003, Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review, Ann Intern Med, 139, 753, 10.7326/0003-4819-139-9-200311040-00010 Messé, 2016, Practice advisory: Recurrent stroke with patent foramen ovale (update of practice parameter): report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology, Neurology, 87, 815, 10.1212/WNL.0000000000002961 Overell, 2000, Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies, Neurology, 55, 1172, 10.1212/WNL.55.8.1172 Srivastava, 1997, Images in clinical medicine. Paradoxical embolism–thrombus in transit through a patent foramen ovale, N Engl J Med, 337, 681, 10.1056/NEJM199709043371005 Carroll, 2013, Closure of patent foramen ovale versus medical therapy after cryptogenic stroke, N Engl J Med, 368, 1092, 10.1056/NEJMoa1301440 Meier, 2013, Percutaneous closure of patent foramen ovale in cryptogenic embolism, N Engl J Med, 368, 1083, 10.1056/NEJMoa1211716 Oliva, 2022, Incidence of new-onset atrial fibrillation after transcatheter patent foramen ovale closure using 15 years of Ontario administrative health data, Heart Rhythm, 19, 1414, 10.1016/j.hrthm.2022.04.006 Guedeney, 2022, Supraventricular arrhythmia following patent foramen ovale percutaneous closure, JACC Cardiovasc Interv, 15, 2315, 10.1016/j.jcin.2022.07.044 Singh, 2017, Factors associated with cardiac electrophysiologist assessment and catheter ablation procedures in patients with atrial fibrillation, JACC Clin Electrophysiol, 3, 302, 10.1016/j.jacep.2016.09.003 Burow, 2008, Atrial fibrillation following device closure of patent foramen ovale, Cardiology, 111, 47, 10.1159/000113427 Thijs, 2016, Predictors for atrial fibrillation detection after cryptogenic stroke: results from CRYSTAL AF, Neurology, 86, 261, 10.1212/WNL.0000000000002282 Merkler, 2017, Safety outcomes after percutaneous transcatheter closure of patent foramen ovale, Stroke, 48, 3073, 10.1161/STROKEAHA.117.018501 Wallenborn, 2013, Recurrent events after percutaneous closure of patent foramen ovale, Catheter Cardiovasc Interv, 82, 541, 10.1002/ccd.24511 Ugowe, 2018, Racial and ethnic differences in the prevalence, management, and outcomes in patients with atrial fibrillation: a systematic review, Heart Rhythm, 15, 1337, 10.1016/j.hrthm.2018.05.019